Immunome (NASDAQ:IMNM) Earns “Outperform” Rating from Wedbush

Immunome (NASDAQ:IMNM)‘s stock had its “outperform” rating restated by Wedbush in a research report issued on Monday,RTT News reports. They presently have a $33.00 price objective on the stock. Wedbush’s target price would suggest a potential upside of 251.81% from the stock’s current price.

Several other equities analysts have also recently weighed in on the company. Stephens began coverage on Immunome in a report on Friday, November 8th. They issued an “overweight” rating and a $30.00 price objective for the company. Piper Sandler dropped their price target on Immunome from $23.00 to $21.00 and set an “overweight” rating for the company in a research note on Thursday, November 14th. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Immunome has a consensus rating of “Buy” and an average target price of $28.83.

Immunome Trading Down 6.6 %

NASDAQ IMNM opened at $9.38 on Monday. The company has a market cap of $585.47 million, a price-to-earnings ratio of -1.16 and a beta of 1.90. The company has a 50 day moving average of $11.72 and a 200-day moving average of $12.98. Immunome has a 1-year low of $8.97 and a 1-year high of $30.96.

Insider Activity

In other Immunome news, CEO Clay B. Siegall bought 66,057 shares of the firm’s stock in a transaction on Thursday, November 21st. The shares were purchased at an average price of $9.54 per share, for a total transaction of $630,183.78. Following the completion of the transaction, the chief executive officer now directly owns 485,693 shares in the company, valued at approximately $4,633,511.22. The trade was a 15.74 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, CTO Philip Tsai bought 21,000 shares of the company’s stock in a transaction dated Thursday, November 21st. The stock was bought at an average cost of $9.43 per share, with a total value of $198,030.00. Following the acquisition, the chief technology officer now directly owns 21,000 shares of the company’s stock, valued at approximately $198,030. The trade was a ∞ increase in their position. The disclosure for this purchase can be found here. In the last quarter, insiders have acquired 102,862 shares of company stock worth $978,045. Insiders own 8.60% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of IMNM. Marshall Wace LLP grew its position in Immunome by 228.5% during the 2nd quarter. Marshall Wace LLP now owns 1,713,325 shares of the company’s stock worth $20,731,000 after acquiring an additional 1,191,774 shares during the last quarter. Janus Henderson Group PLC boosted its stake in shares of Immunome by 10.3% during the third quarter. Janus Henderson Group PLC now owns 3,488,121 shares of the company’s stock valued at $50,971,000 after purchasing an additional 324,614 shares in the last quarter. Charles Schwab Investment Management Inc. grew its holdings in shares of Immunome by 217.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 442,477 shares of the company’s stock worth $6,469,000 after purchasing an additional 302,916 shares during the last quarter. Victory Capital Management Inc. increased its stake in shares of Immunome by 48.1% in the third quarter. Victory Capital Management Inc. now owns 730,785 shares of the company’s stock valued at $10,684,000 after buying an additional 237,497 shares during the period. Finally, AXA S.A. bought a new position in Immunome in the 2nd quarter valued at approximately $2,174,000. 44.58% of the stock is currently owned by institutional investors.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.